Yacca Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 15-07-2024
- Paid Up Capital ₹ 1.00 M
as on 15-07-2024
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 319.96 M
as on 15-07-2024
- Satisfied Charges ₹ 44.76 M
as on 15-07-2024
- Revenue 14.81%
(FY 2021)
- Profit 1.87%
(FY 2021)
- Ebitda 11.11%
(FY 2021)
- Net Worth 2.44%
(FY 2021)
- Total Assets -3.86%
(FY 2021)
About Yacca Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹32.00 Cr. The company has closed loans amounting to ₹4.48 Cr, as per Ministry of Corporate Affairs (MCA) records.
Anjali Bansal, Pankaj Bansal, Prateek Bansal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231UP1989PTC011458
- Company No.
011458
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Bulandshahr, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Yacca Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pankaj Bansal  | Managing Director | 11-Dec-1989 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Aayush Bansal | Director | 11-Aug-2018 | Current |
| Anjali Bansal | Director | 11-Dec-1989 | Current |
| Prateek Bansal | Director | 11-Aug-2018 | Current |
Financial Performance and Corporate Structure Insights of Yacca Pharmaceuticals.
Yacca Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 14.81% increase. The company also saw a slight improvement in profitability, with a 1.87% increase in profit. The company's net worth moved up by a moderate rise of 2.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Yacca Pharmaceuticals?
Unlock access to Yacca Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Yacca Lifesciences Private Limited
Active 9 years 1 monthAnjali Bansal, Pankaj Bansal and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Sep 2022 | ₹19.69 Cr | Open |
Hdfc Bank Limited Creation Date: 16 Sep 2020 | ₹12.21 Cr | Open |
Pankaj K. Bansal Creation Date: 16 May 1994 | ₹1.00 M | Open |
How Many Employees Work at Yacca Pharmaceuticals?
Yacca Pharmaceuticals has a workforce of 31 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Yacca Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yacca Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
